… apixaban, argatroban, enoxaparin, heparin, eptifibatide, and tirofiban. Apixaban and heparin
… mortality among individuals hospitalized with COVID-19.This has piqued interest in the use …

… effects of different types of anticoagulants, such as low-molecular-weight heparin (LMWH)
and direct oral anticoagulants … all-cause mortality in post-discharge patients with COVID-19 …

… ,3 and most cases received low molecular weight heparin (LMWH) as … with COVID-19,
resulting in decreased mortality without increasing the risk of bleeding.9 In our case, apixaban …

… that COVID-19 patients on chronic anticoagulant therapy … of the role of heparin in the case
of COVID-19 infection, leading … hospitalized for COVID-19, in whom mortality was strongly …

… mortality. Tocilizumab did not provide additional benefits to heparin in COVID-19 … Anticoagulant
therapy for COVID-19: What we have learned and what are the unanswered questions? …

… by 80 mg once daily) and apixaban (2.5 mg twice daily) according to … with (Low Molecular
Weight Heparin, LMWH) or DOAC for a … is high and associated with a higher risk of mortality: A …

… caused more than 6.3 million deaths. The studies showed … heparin, direct oral anticoagulant
drugs (edoxaban, apixaban, … , enoxaparin, 40–60 mg daily) in very sick COVID-19 patients …

… inflammatory parameters and mortality in COVID-19 patients, … of anticoagulation in even
critically ill COVID-19 patients, beyond … ill patients without COVID-19 receiving standard heparin-…

… two doses of apixaban for patients with COVID-19 infection who … heparin (UFH) unless
specific contraindications exist. … The mortality rate in children hospitalized with COVID-19 or MIS-…

… -molecular weight and unfractionated heparin, but not all patients … a decrease in mortality
of critical COVID-19 patients with … of the patients received rivaroxaban and the rest apixaban. …